FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2966920962> ?p ?o ?g. }

• W2966920962 endingPage "484" @default.
• W2966920962 startingPage "475" @default.
• W2966920962 abstract "Topoisomerase II (TOP2) poisons are effective cytotoxic anticancer agents that stabilize the normally transient TOP2-DNA covalent complexes formed during the enzyme reaction cycle. These drugs include etoposide, mitoxantrone, and the anthracyclines doxorubicin and epirubicin. Anthracyclines also exert cell-killing activity via TOP2-independent mechanisms, including DNA adduct formation, redox activity, and lipid peroxidation. Here, we show that anthracyclines and another intercalating TOP2 poison, mitoxantrone, stabilize TOP2-DNA covalent complexes less efficiently than etoposide, and at higher concentrations they suppress the formation of TOP2-DNA covalent complexes, thus behaving as TOP2 poisons at low concentration and inhibitors at high concentration. We used induced pluripotent stem cell (iPSC)-derived human cardiomyocytes as a model to study anthracycline-induced damage in cardiac cells. Using immunofluorescence, our study is the first to demonstrate the presence of topoisomerase IIβ (TOP2B) as the only TOP2 isoform in iPSC-derived cardiomyocytes. In these cells, etoposide robustly induced TOP2B covalent complexes, but we could not detect doxorubicin-induced TOP2-DNA complexes, and doxorubicin suppressed etoposide-induced TOP2-DNA complexes. In vitro, etoposide-stabilized DNA cleavage was attenuated by doxorubicin, epirubicin, or mitoxantrone. Clinical use of anthracyclines is associated with cardiotoxicity. The observations in this study have potentially important clinical consequences regarding the effectiveness of anticancer treatment regimens when TOP2-targeting drugs are used in combination. These observations suggest that inhibition of TOP2B activity, rather than DNA damage resulting from TOP2 poisoning, may play a role in doxorubicin cardiotoxicity. SIGNIFICANCE STATEMENT: We show that anthracyclines and mitoxantrone act as topoisomerase II (TOP2) poisons at low concentration but attenuate TOP2 activity at higher concentration, both in cells and in in vitro cleavage experiments. Inhibition of type II topoisomerases suppresses the action of other drugs that poison TOP2. Thus, combinations containing anthracyclines or mitoxantrone and etoposide may reduce the activity of etoposide as a TOP2 poison and thus reduce the efficacy of drug combinations." @default.
• W2966920962 created "2019-08-22" @default.
• W2966920962 creator A5022208465 @default.
• W2966920962 creator A5036925440 @default.
• W2966920962 creator A5037118774 @default.
• W2966920962 creator A5056627922 @default.
• W2966920962 creator A5062981053 @default.
• W2966920962 creator A5064384359 @default.
• W2966920962 creator A5073284312 @default.
• W2966920962 creator A5078746379 @default.
• W2966920962 date "2019-08-09" @default.
• W2966920962 modified "2023-10-14" @default.
• W2966920962 title "Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations" @default.
• W2966920962 cites W130020229 @default.
• W2966920962 cites W1479874532 @default.
• W2966920962 cites W1514525963 @default.
• W2966920962 cites W1553801508 @default.
• W2966920962 cites W1562335567 @default.
• W2966920962 cites W1589900156 @default.
• W2966920962 cites W1929164375 @default.
• W2966920962 cites W1970288681 @default.
• W2966920962 cites W1983822030 @default.
• W2966920962 cites W1988862874 @default.
• W2966920962 cites W1990619967 @default.
• W2966920962 cites W1994490060 @default.
• W2966920962 cites W2010183849 @default.
• W2966920962 cites W2016254453 @default.
• W2966920962 cites W2017742066 @default.
• W2966920962 cites W2022532929 @default.
• W2966920962 cites W2033484193 @default.
• W2966920962 cites W2034862301 @default.
• W2966920962 cites W2039595064 @default.
• W2966920962 cites W2047505314 @default.
• W2966920962 cites W2048335618 @default.
• W2966920962 cites W2056441912 @default.
• W2966920962 cites W2058142120 @default.
• W2966920962 cites W2061781942 @default.
• W2966920962 cites W2067756383 @default.
• W2966920962 cites W2068577449 @default.
• W2966920962 cites W2069891078 @default.
• W2966920962 cites W2071388314 @default.
• W2966920962 cites W2077982832 @default.
• W2966920962 cites W2079755465 @default.
• W2966920962 cites W2080045669 @default.
• W2966920962 cites W2083599207 @default.
• W2966920962 cites W2106926141 @default.
• W2966920962 cites W2107864294 @default.
• W2966920962 cites W2112902082 @default.
• W2966920962 cites W2122347701 @default.
• W2966920962 cites W2126232974 @default.
• W2966920962 cites W2132960195 @default.
• W2966920962 cites W2138633970 @default.
• W2966920962 cites W2140182328 @default.
• W2966920962 cites W2150475243 @default.
• W2966920962 cites W2157391676 @default.
• W2966920962 cites W2159302057 @default.
• W2966920962 cites W2161800003 @default.
• W2966920962 cites W2235523066 @default.
• W2966920962 cites W2252841611 @default.
• W2966920962 cites W2297718137 @default.
• W2966920962 cites W2309693971 @default.
• W2966920962 cites W2341351767 @default.
• W2966920962 cites W2341695868 @default.
• W2966920962 cites W2346631874 @default.
• W2966920962 cites W2409651531 @default.
• W2966920962 cites W2416872489 @default.
• W2966920962 cites W2508590611 @default.
• W2966920962 cites W2553279548 @default.
• W2966920962 cites W2600231501 @default.
• W2966920962 cites W2802006837 @default.
• W2966920962 cites W2805734855 @default.
• W2966920962 cites W4213105243 @default.
• W2966920962 cites W4239139991 @default.
• W2966920962 cites W4243549408 @default.
• W2966920962 cites W4253868125 @default.
• W2966920962 cites W624930994 @default.
• W2966920962 doi "https://doi.org/10.1124/mol.119.117259" @default.
• W2966920962 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6744389" @default.
• W2966920962 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31399497" @default.
• W2966920962 hasPublicationYear "2019" @default.
• W2966920962 type Work @default.
• W2966920962 sameAs 2966920962 @default.
• W2966920962 citedByCount "33" @default.
• W2966920962 countsByYear W29669209622019 @default.
• W2966920962 countsByYear W29669209622020 @default.
• W2966920962 countsByYear W29669209622021 @default.
• W2966920962 countsByYear W29669209622022 @default.
• W2966920962 countsByYear W29669209622023 @default.
• W2966920962 crossrefType "journal-article" @default.
• W2966920962 hasAuthorship W2966920962A5022208465 @default.
• W2966920962 hasAuthorship W2966920962A5036925440 @default.
• W2966920962 hasAuthorship W2966920962A5037118774 @default.
• W2966920962 hasAuthorship W2966920962A5056627922 @default.
• W2966920962 hasAuthorship W2966920962A5062981053 @default.
• W2966920962 hasAuthorship W2966920962A5064384359 @default.
• W2966920962 hasAuthorship W2966920962A5073284312 @default.
• W2966920962 hasAuthorship W2966920962A5078746379 @default.
• W2966920962 hasBestOaLocation W29669209621 @default.

• next